$AMRS & Biogen. $BIIB Collaboration $300+ #Biotech Stock Amyris recently announced partnership with Biogen, Inc. to develop alternative cell lines supporting production of therapeutics, marking second major partnership in biopharma market, which is now positioned to become Amyris’s largest opportunity for collaborations. The Biogen partenrship is the most exciting of all,” CEO John Melo said,. With it, Amyris he said would make “ a transformative change to biopharma where partner would be able to employ [Amyris biotechnology] instead of using cells from mammals. Others have attempted and failed, but we are positioned to deliver life saving therapeutics and make them more widely available. This could be game changing for biopharmaceuticals, and Biogen will fully fund the development.” http://www.biofuelsdigest.com/bdigest/2016/08/14/amyris-the-new-colossus-aims-to-unlock-its-golden-door/
News 
Market Data 
Discover 
